Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Buy” from Analysts

Posted by Geri Gentry on May 17th, 2026

Shares of Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) have been given a consensus recommendation of “Buy” by the thirteen analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, nine have issued a buy rating and three have issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $20.30.

A number of brokerages have commented on CLYM. Oppenheimer raised their price target on shares of Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 21st. Robert W. Baird set a $21.00 price target on shares of Climb Bio in a research note on Wednesday, May 6th. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial began coverage on shares of Climb Bio in a research note on Tuesday, March 17th. They set a “buy” rating and a $17.00 price target for the company. Finally, Raymond James Financial began coverage on shares of Climb Bio in a research note on Tuesday, March 10th. They set a “strong-buy” rating and a $25.00 price target for the company.

Get Our Latest Research Report on Climb Bio

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new position in shares of Climb Bio in the second quarter valued at approximately $46,000. Qube Research & Technologies Ltd bought a new position in shares of Climb Bio in the second quarter valued at approximately $43,000. Virtu Financial LLC bought a new position in shares of Climb Bio in the fourth quarter valued at approximately $43,000. AQR Capital Management LLC bought a new position in shares of Climb Bio in the first quarter valued at approximately $27,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Climb Bio in the first quarter valued at approximately $715,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio News Summary

Here are the key news stories impacting Climb Bio this week:

Positive Sentiment: HC Wainwright raised earnings estimates across several quarters and fiscal years, suggesting analysts see Climb Bio’s losses narrowing faster than previously expected, while keeping a Buy rating and a $20 target.
Positive Sentiment: Wedbush reiterated its Buy rating on Climb Bio, reinforcing bullish analyst sentiment around the stock.
Positive Sentiment: Another analyst note lifted the price target on CLYM by 18.34% to $19.62, signaling higher valuation expectations.
Neutral Sentiment: Climb Bio announced it will present new budoprutug clinical data at the European Hematology Association 2026 Congress, an event that could draw investor attention but does not yet change the company’s fundamentals.

Climb Bio Stock Performance

NASDAQ CLYM opened at $10.80 on Friday. The firm has a 50-day simple moving average of $8.39 and a 200 day simple moving average of $5.44. Climb Bio has a twelve month low of $1.16 and a twelve month high of $12.48. The stock has a market cap of $618.41 million, a PE ratio of -13.85 and a beta of 0.02.

Climb Bio (NASDAQ:CLYM – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.06. Research analysts forecast that Climb Bio will post -0.9 earnings per share for the current fiscal year.

Climb Bio Company Profile

(Get Free Report)

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.